Effects of Lactobacillus Crispatus LCr86 on Bacterial Vaginosis and Ovarian Function in Women

Launched by WECARE PROBIOTICS CO., LTD. · Feb 11, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a specific probiotic called Lactobacillus crispatus LCr86 on women who have bacterial vaginosis (BV), a common condition that affects vaginal health. The goal is to see how well this probiotic works when combined with antibiotics to help clear up the infection, prevent it from coming back, and improve the balance of bacteria in the vagina.

To participate in this study, women must be between 18 and 65 years old, have a history of sexual activity, and have a diagnosis of BV confirmed by a specific scoring system. However, women with other types of infections or certain health conditions, those who are pregnant or breastfeeding, or those who have used antibiotics recently cannot join. If eligible, participants will receive treatment and will be monitored for changes in their condition. This trial is not yet recruiting, so there will be more information available as it gets underway.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 to 65 years of age, history of sexual activity, premenopausal women;
• • 2. Nugent score ≥ 7 for diagnosis of BV;
• • 3. Signed informed consent.
• Exclusion Criteria:
• • 1. Mixed vaginitis, such as vulvovaginal candidiasis (VVC), Trichomonas vaginalis (TV) infection, Chlamydia trachomatis (CT) infection, or gonococcal vaginitis;
• • 2. History of systemic organic or psychiatric disease;
• • 3. Planned pregnancy, breastfeeding, or menstruation;
• • 4. Have used any antibiotics within 5 days of disease onset;
• • 5. Long-term use of contraceptives or immunosuppressants;
• • 6. Hypersensitivity or allergy to known components of the study drug.